CD274 and cervical carcinoma: Another notable phase III trial that assessed first-line combination therapy for metastatic or recurrent cervical cancer is BEATcc (NCT03556839), which indicated a benefit of adding atezolizumab, anti-PD-L1 inhibitor, to the GOG-240 trial regimen (chemotherapy with bevacizumab) [14] in patients with metastatic/recurrent cervical cancer [25].